Vascular endothelial growth factor 2
US6040157A · kind A · utility
96Cited by
9References
75Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 1998 |
| Grant date | Mar 21, 2000 |
| Priority date | — |
| Expiry date | Mar 13, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeuticall sefl fragments, analogs, or derivatives thereof, and DNA (RNA) enco such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.